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Opioids remain the standard for analgesic care; how-
ever, adverse effects of systemic treatments contra-
indicate long-term administration. While most clin-
ical opioids target mu opioid receptors (MOR),
those that target the delta class (DOR) also demon-
strate analgesic efficacy. Furthermore, peripherally
restrictive opioids represent an attractive direction
for analgesia. However, opioid receptors including
DOR are analgesically incompetent in the absence
of inflammation. Here, we report that G protein-
coupled receptor kinase 2 (GRK2) naively associates
with plasma membrane DOR in peripheral sensory
neurons to inhibit analgesic agonist efficacy. This
interaction prevents optimal Gb subunit association
with the receptor, thereby reducing DOR activity.
Importantly, bradykinin stimulates GRK2 movement
away from DOR and onto Raf kinase inhibitory
protein (RKIP). protein kinase C (PKC)-dependent
RKIP phosphorylation induces GRK2 sequestration,
restoring DOR functionality in sensory neurons.
Together, these results expand the known function
of GRK2, identifying a non-internalizing role to main-
tain peripheral DOR in an analgesically incompetent
state.INTRODUCTION
Opioid agonists are essential therapeutic strategies in the
treatment of pain. Opioids produce analgesia by activating
G protein-coupled receptors (GPCRs) known as mu (m-, MOR),
delta (d-, DOR), and kappa (k-, KOR) opioid receptors. Tradition-
ally, MOR analgesics are prescribed for the treatment of severe
pain. However, DOR agonists have reduced side effect profiles
compared to MOR agonists in rodent and non-human primate
models (Vanderah, 2010). Like other opioid receptors, DOR pri-
marily signals downstream through Gai and Gbg subunits (Alves2686 Cell Reports 16, 2686–2698, September 6, 2016 ª 2016 The Au
This is an open access article under the CC BY-NC-ND license (http://et al., 2004) that inhibit neuronal depolarization by decreasing
cAMP activity (Law and Bergsbaken, 1995) and inhibiting
voltage-gated Ca2+ channels (VGCCs) (Ford et al., 1998). In an
effort to reduce systemic side effects and abuse potential,
peripherally restricted DOR agonists serve as an attractive alter-
native to systemic opioid therapies. However, multiple reports
demonstrate that peripheral DOR analgesic competence re-
quires an inflammatory pre-stimulus (Stein et al., 1989; Patward-
han et al., 2005, 2006; Gave´riaux-Ruff et al. 2008; Rowan et al.,
2009; Pettinger et al., 2013). Importantly, peripheral DOR incom-
petence is not well understood and could provide important
insight on the role of inflammatory mediators in peripheral opioid
receptor regulation.
Peripheral tissues release inflammatory mediators such as
bradykinin (BK) in response to injury (Levy and Zochodne,
2000). Nociceptive responses following BK administration are
mediated via Gaq/11-coupled GPCRs expressed by primary
afferent neurons that co-express opioid receptors (Steranka
et al., 1988; Patwardhan et al., 2005; Petcu et al., 2008).
Importantly, BK induces rapid functional competence of DOR
antinociception (Patwardhan et al., 2005; Rowan et al., 2009),
indicating that peripheral DOR exists naively in a desensitized
state. Inflammation-induced DOR analgesic competence at
peripherally restrictive doses is known as ‘‘priming’’ (Patwardhan
et al., 2005; Rowan et al., 2009; Pradhan et al., 2013), yet a
mechanism for this phenomenon remains unknown. Recent
work has identified a role for protein kinase C (PKC) (Patwardhan
et al., 2005; Rowan et al., 2009), which agrees with work demon-
strating that BK activation drives phospholipase C (PLC) activity
to stimulate downstream PKC isoforms (Fu et al., 1989; Tippmer
et al., 1994; Graness et al., 1997). Indeed, careful dissection of
this mechanism would increase the application of peripherally
restrictive DOR agonists to treat pain and reduce centrally
mediated negative side effects associated with systemic MOR
agonist administration.
Agonist-induced desensitization of DOR is dependent on hier-
archical phosphorylation by G protein-coupled receptor kinase 2
(GRK2) (Kouhen et al., 2000; Guo et al., 2000). In contrast, the
scaffolding protein Raf kinase inhibitory protein (RKIP) facilitates
opioid receptor activity (Kroslak et al., 2001). An important regu-
latory feature of RKIP modulation of GPCR activity is directthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Functional DOR Competence in
Sensory Neurons
(A and B) Dose response for DPDPE inhibition of
KCl (50 mM)-evoked Ca2+ influx in (A) TG or (B)
DRG pretreated with vehicle or BK (200 nM, 5 min)
following 2 hr serum-starvation. ***p < 0.005 versus
vehicle; (A) n = 26–57 and (B) n = 17–39 neurons/
dose; two-way ANOVA Bonferroni post hoc;
mean ± SEM. Least-squares fit (best-fit) variable
slope curves used to determine IC50 for vehicle
(dotted line) and BK (solid line) and 95% confi-
dence intervals (gray).
(C) Effect of naltrindole pretreatment on DPDPE
(1 mM) inhibition of KCl-evoked Ca2+ influx in
DRG neurons pretreated vehicle or naltrindole
(10 nM, 5 min) prior to vehicle or BK (200 nM,
5 min) treatment following 2 hr serum-starvation.
**p < 0.01; ns, no significance; n = 14–28 DRG/
group; two-way ANOVA Bonferroni post hoc;
mean ± SEM.
(D) Comparison of DPDPE (1 mM) versus SNC 80
(1 mM) inhibition of KCl-evoked Ca2+ influx in DRG
neurons pretreated with vehicle or BK (200 nM,
5min) following 2 hr serum-starvation. ***p < 0.005;
n = 24–34DRG/group; two-way ANOVABonferroni
post hoc; mean ± SEM.
(E and F) Representative traces (E) and quantifi-
cation (F) of DPDPE (1 mM) inhibition of VGCCs in
DRG neurons (20–35 pF) pretreated with vehicle or
BK (200 nM, 10 min) following 2 hr serum-starva-
tion. ***p < 0.005; n = 4–9 DRG/group; one-way
ANOVA Bonferroni post hoc; mean ± SEM.
See also Figures S1 and S2.phosphorylation by PKC, which induces RKIP dimerization and
subsequent sequestration of GRK2 (Lorenz et al., 2003; Deiss
et al., 2012). This represents a fundamental research effort to
identify that GRK2 chronically downregulates DOR antinocicep-
tion. Furthermore, we provide support for the hypothesis that BK
primes DOR analgesic competency in peripheral sensory neu-
rons via RKIP sequestration of GRK2.
RESULTS
DORCompetence in Naive and Primed Sensory Neurons
Opioids elicit their analgesic effects, in part, via receptor-medi-
ated inhibition of VGCCs (Stein and Zo¨llner, 2009). In sensory
neurons, transient exposure to 50 mM KCl evokes a measure-
able increase in intracellular Ca2+, which is attributable to an
influx of extracellular Ca2+ through VGCCs following neuronal
depolarization (Khasabova et al., 2002). Activation of DOR
inhibits KCl-evoked Ca2+ influx through L-type, N-type, andCell ReporP/Q-type VGCCs, as well as KCl-induced
neurotransmitter release in DRG (Khasa-
bova et al., 2004). Multiple investigators
have previously quantified opioid inhibi-
tion of VGCCs via KCl-evoked Ca2+ influx
in cultured sensory neurons (Khasabova
et al., 2004; Pettinger et al., 2013). Thus,
DOR agonist inhibition of KCl-evokedCa2+ influx is a validated method for quantifying DOR activity in
a population of sensory neurons. Given that DOR is not ex-
pressed in all peripheral sensory neurons, this method circum-
vents the limitation of user bias when determining whether native
DOR is functionally expressed within a given cell and eliminates
potential changes to receptor activity and/or biochemistry
that result from receptor-fusion proteins introduced by gene
targeting.
DOR activity was assessed in adult rat TG and DRG CAP-sen-
sitive neurons (Figures 1A and 1B). At doses ranging from 1 nM to
1 mM, the DOR agonist [D-Pen(2),D-Pen(5)]-enkephalin (DPDPE)
did not significantly inhibit Ca2+ influx elicited by KCl in vehicle-
treated TG or DRG neurons. However, at doses above 1 mM,
DPDPE efficiently inhibited KCl-evoked Ca2+ accumulation in
both vehicle-treated TG and DRG. Pretreatment with BK
(200 nM) significantly increased the potency of DPDPE to inhibit
KCl-evoked Ca2+ influx in both populations of TG and DRG neu-
rons at 1 mM (also known as the BK priming effect). Importantly,ts 16, 2686–2698, September 6, 2016 2687
equimolar dose of DOR agonist DADLE has previously been
shown to increase the population of TG capable of DOR-medi-
ated inhibition of VGCCs (Pettinger et al., 2013). Thus, 1 mM
DPDPE was the dose used for the remainder of this study in
both cultured TG and DRG neurons. IC50 values for DPDPE
were 6.91 3 106 M versus 5.21 3 106 M for vehicle-treated
TG and DRG, respectively. IC50 values for DPDPE were 6.15 3
107 M versus 7.39 3 107 M for BK-treated TG and DRG,
respectively. The efficacy or maximal response to DPDPE was
unaltered by BK in both TG andDRG. Thus, the BK priming effect
on DOR activity was indistinguishable between TG and DRG
neurons.
The response to DPDPE (1 mM) treatment in DRG pretreated
with BK (200 nM; 5 min) was blocked when co-treated with irre-
versible selective DOR antagonist naltrindole (10 nM, 50 3 Ki;
5 min) (Figure 2C). This demonstrates that inhibition of KCl-
evoked Ca2+ influx by DPDPE at the selected dose is mediated
by DOR. SNC 80 was included as a more selective nonpeptide
agonist for DOR, compared to peptide agonist DPDPE (Calderon
et al., 1994). At a concentration of SNC 80 equal to the dose used
for DPDPE and previously verified to inhibit VGCCs in sensory
neurons (Rowan et al., 2014), SNC80 (1 mM) and DPDPE (1 mM)
equally inhibited DOR activity in DRG when primed by BK
(200 nM; 5 min) (Figure 1D). Furthermore, patch-clamp electro-
physiology revealed that DPDPE (1 mM) significantly inhibited
VGCCs in DRG neurons (20–35 pF) only following BK (200 nM)
pretreatment (Figures 1E and 1F). Collectively, these studies
demonstrate that DOR is functionally incompetent unless primed
by BK in peripheral sensory neurons.
GRK2 Modulation of Functional DOR Competence
Agonist-induced DOR activation recruits GRK2, which stimu-
lates receptor phosphorylation that induces canonical receptor
desensitization and internalization (Kouhen et al., 2000; Guo
et al., 2000; Hong et al., 2009; Xu et al., 2010). Recent work in
immortalized cells demonstrated that GRK2 may chronically
remain associated with a GPCR in the absence of agonist stim-
ulation, thereby reducing receptor competence (Namkung et al.,
2009). To explain the chronic analgesic incompetence of periph-
eral DOR under naive conditions, we first used co-immunopre-
cipitation (coIP) analyses to investigate the possibility that
GRK2 might be constitutively associated with DOR in primary
neuronal culture (Figure 2A). In plasma membrane (PM) prepara-
tions from serum-starved, vehicle-treated TG cultures, DOR co-
immunoprecipitates with GRK2. Notably, there is a significant
reduction in GRK2 co-immunoprecipitation with DOR following
treatment with BK (200 nM; 5 min). These data indicate that in
the absence of agonist stimulation, GRK2 is statically bound to
DOR under naive conditions and provides support that BK in-
duces a reduction in DOR association with GRK2 at the PM.
To evaluate the role of GRK2 in functional DOR competence
under naive and primed conditions, we employed small inter-
fering RNA (siRNA)-mediated knock down of GRK2 expression
and assessed DOR activity using Ca2+ imaging and patch-clamp
electrophysiology. To demonstrate the specificity of this molec-
ular approach, we first assessed the efficiency of GRK2 knock
down relative to b-actin and found a 76% reduction in normal-
ized GRK2 protein expression one day post-transfection (Fig-2688 Cell Reports 16, 2686–2698, September 6, 2016ure 2B). Next, we determined DOR competency in the neuronal
population of primary DRG following siRNA-mediated knock
down of GRK2 using Ca2+ imaging. BK pretreatment (200 nM;
5 min) significantly increased DPDPE inhibition of KCl-evoked
Ca2+ influx in mock-transfected DRG neurons (Figures 2C and
2D). However, in DRG cultures transfected with FITC-GRK2
siRNA, the increase in DPDPE inhibition of KCl-evoked Ca2+
influx was independent of BK pretreatment. Similarly, DPDPE
significantly inhibited VGCCs only following priming by BK
(200 nM) in mock-treated small to medium DRG neurons (Fig-
ure 2F). Importantly, small to medium DRG neurons transfected
with FITC-GRK2 siRNA did not require BK pretreatment to evoke
significant DPDPE inhibition of VGCCs. These data indicate that
GRK2 participates in functional DOR incompetence in cultured
DRG neurons.
GRK2 kinase activity regulates homologous desensitization
of many GPCRs through receptor-G protein uncoupling and re-
ceptor internalization following phosphorylation (Premont et al.,
1995). Following DOR agonist stimulation, GRK2 hierarchically
phosphorylates DOR first at Ser363 to mediate receptor desen-
sitization through G protein uncoupling and then at Thr358 to
initiate internalization of the receptor to further attenuate
signaling (Guo et al., 2000; Kouhen et al., 2000; Xu et al.,
2010). To determine whether BK affects GRK2 phosphorylation
of DOR, we used a phosphorylation site-specific antibody for
DOR at Ser363 (Figure 3A). In PM preparations from serum-
starved, vehicle-treated TG cultures, DOR is phosphorylated at
Ser363. Interestingly, DOR phosphorylation at Ser363 remains
unchanged following pretreatment with BK (200 nM; 5 min).
These data demonstrate that BK does not affect GRK2-medi-
ated phosphorylation of DOR at its primary desensitization site.
To assess whether GRK2 kinase activity supports functional
DOR incompetence in primary DRG cultures, we overexpressed
GRK2 or a kinase-inactive mutant that maintains the ability to
interact with GPCRs (K220R) (Kong et al., 1994) and measured
DOR inhibition of KCl-evoked Ca+2 influx in vehicle-treated and
BK-treated conditions. BK pretreatment (200 nM; 5 min) signifi-
cantly increased DPDPE inhibition of KCl-evoked Ca2+ influx in
GFP-positive DRG nucleofected with empty vector (E.V.) (Fig-
ures 3B and 3C). However, in DRG nucleofected with GRK2 or
K220R, BK was unable to induce DPDPE inhibition of KCl-
evoked Ca2+ influx over vehicle-treated DRG. These data
demonstrate that GRK2 kinase activity is not required for
GRK2 modulation of functional DOR incompetence in primary
sensory neurons.
GRK2Modulation of DOR Analgesic Competence In Vivo
After we identified a role for GRK2 modulation of functional
DOR incompetence in sensory neurons in vitro, we measured
physiologic peripheral DOR analgesic incompetence in vivo. In
this study, we employed antisense-oligodeoxynucleotides (AS-
ODN) against GRK2 mRNA to knock down GRK2 expression in
a model of BK priming of peripheral DOR. Intrathecal (i.t.) injec-
tions of GRK2 AS-ODN over 3 days significantly reduced GRK2
expression in peripheral sensory nerves (Ferrari et al., 2012). Uti-
lizing the same AS-ODN in this study, daily i.t. injections of GRK2
AS-ODN (30 mg/day) over 3 days nearly ablated GRK2 protein
expression in both ipsilateral and contralateral DRG (Figures
Figure 2. GRK2 Modulation of DOR Activity
(A) Crude PM coIP from TG cultures serum-starved for 18 hr and treated with vehicle or BK (200 nM, 5min). *p < 0.05; n = 3 independent trials; unpaired two-tailed
Student’s t test; mean ± SEM.
(B) WCL from 2 hr serum-starved TG cultures transfected in mock fashion or with mismatch, GRK2, or FITC-GRK2 siRNA. ***p < 0.005; ns, no significance; n = 6
independent trials; one-way ANOVA Bonferroni post hoc; mean ± SEM.
(C and D) Cumulative traces (C) and quantification (D) of DPDPE (1 mM) inhibition of KCl (50 mM)-evoked Ca2+ influx in DRG (mock-treated or transfected with
FITC-GRK2 siRNA) pre-treated with vehicle or BK (200 nM, 5 min) following 2 hr serum-starvation. ***p < 0.005; n = 22–37 DRG/group; two-way ANOVA
Bonferroni post hoc; mean ± SEM.
(E) DPDPE (1 mM) inhibition of VGCCs in DRG (mock-treated or transfected with FITC-GRK2 siRNA) pre-treated with vehicle or BK (200 nM, 10 min) following 2 hr
serum-starvation. ***p < 0.005; n = 5–8 DRG/group; two-way ANOVA Bonferroni post hoc; mean ± SEM.
See also Figure S3.4A and 4B). To assess whether GRK2 knock down affects DOR
analgesic competence, we assessed DPDPE inhibition of PGE2-
induced mechanical and thermal allodynia following BK priming
in MM-ODN- and AS-ODN-treated rats (Figures 4C–4H). In MM-
ODN-treated animals, injection of a peripherally restrictive dose
of DPDPE (20 mg) (Rowan et al., 2009) into the hindpaw did not
block PGE2 (0.3 mg)-inducedmechanical or thermal allodynia un-
less primed by BK (25 mg). Similar to functional data, GRK2
knock down eliminated the BK priming requirement for func-
tional competence of the DOR in vivo. Surprisingly, both BK-
induced mechanical and thermal allodynia remain unchanged
with GRK2 knock down. Although GRK2 is reduced in both
ipsilateral and contralateral DRG, contralateral PWTs and
PWLs remained unchanged from BL. These data suggest that
GRK2 impairs peripheral DOR analgesic competence in vivo.BK Activates PLC-PKC Pathway to Modulate DOR
BK stimulation of B2R activates downstream PLC or cAMP
signaling and leads to PKC or PKA activation, respectively
(Liebmann and Bo¨hmer, 2000). To determine whether kinases
downstream of BK signaling were involved in BK-mediated
GRK2 dissociation from DOR, we employed inhibitors of PLC
(U73122, 10 mM), PKC (GF 109203X [GFX], 10 mM), and PKA
(H-89 20 mM) (Figure S3). BK-induced GRK2 dissociation from
DOR was reversed by inhibitors for PLC and PKC, but not
PKA. These results demonstrate that a PLC-PKC-dependent
pathway is involved in BK-mediated GRK2 dissociation from
DOR in cultured TG neurons.
BK-induced functional DOR competence is mediated by PKC
both in vitro and in vivo (Patwardhan et al., 2005; Rowan et al.,
2009). However, whether other secondmessengers downstreamCell Reports 16, 2686–2698, September 6, 2016 2689
Figure 3. Constitutive DOR Incompetence Is Independent of GRK2 Kinase Activity
(A) DOR phosphorylation at Ser363 in crude PM immunoprecipitates from TG cultures serum-starved for 18 hr and treated with vehicle or BK (200 nM, 5 min). ns,
no significance; n = 3 independent trials; unpaired two-tailed Student’s t test; mean ± SEM.
(B and C) Cumulative traces (B) and quantification (C) of DPDPE (1 mM) inhibition of KCl (50 mM)-evoked Ca2+ influx in nucleofected DRG (overexpression: empty
vector [E.V.] + GFP, GRK2 + GFP, K220R + GFP cDNAs) pretreated with vehicle or BK (200 nM, 5 min) following 2 hr serum-starvation. *p < 0.05; n = 20–31 DRG/
group; two-way ANOVA Bonferroni post hoc; mean ± SEM.of BK-receptor activation mediate DOR priming remains un-
known. Thus, we tested whether inhibitors for PLC (U73122,
10 mM) or PKA (H-89 20 mM) could block the BK effect on DPDPE
inhibition of KCl-evoked Ca2+ influx in CAP-sensitive DRG neu-
rons, using the PKC inhibitor (GFX, 10 mM) as a positive control.
Inhibition of PLC and PKC, but not PKA, blocked BK priming of
functional DOR competence in DRG (Figure S3). In agreement
with GRK2 dissociation from DOR, these data indicate that BK
priming of DOR competence in peripheral sensory neurons is
mediated by the PLC-PKC pathway and not PKA.
Modulation of RKIP in Sensory Neurons
RKIP is an important signal modifier of GPCR signaling. In sen-
sory neurons, BK evokes rapid PKC activation (Delmas et al.,
2002; Cesare et al., 1999). Studies in immortalized cells have
demonstrated that agonist-induced PKC phosphorylation of
RKIP facilitates its self-dimerization, which is crucial for RKIP
association with GRK2 (Corbit et al., 2003; Lorenz et al., 2003;
Deiss et al., 2012). Dimerized RKIP can then sequester GRK2
and hinder GRK2-mediated receptor desensitization. Given its
expression in intact TG and DRG tissue (Figure 5A) and sensi-
tivity to PKC, we hypothesized that BK stimulates PKC-depen-
dent modulation of RKIP in primary sensory neurons.
Previous studies have demonstrated that activation of Gaq-
coupled GPCRs results in PKC phosphorylation of RKIP at
Ser153, followed by RKIP self-dimerization and recruitment of
GRK2 in multiple cell lines (Corbit et al., 2003; Lorenz et al.,
2003; Deiss et al., 2012). We sought to determine whether this2690 Cell Reports 16, 2686–2698, September 6, 2016mechanism occurs in sensory neurons. To determine whether
BK activation of B2R leads to PKC phosphorylation of RKIP,
we utilized a phosphorylation site-specific antibody for RKIP at
Ser153 (Figure 5B). BK (200 nM; 5 min) treatment nearly triples
RKIP phosphorylation at Ser153 in serum-starved TG, which
was blocked by pretreatment with a B2R antagonist (HOE-140;
10 mM; 5 min) or PKC inhibitor (GFX, 10 mM; 5 min). These data
demonstrate that BK stimulation of B2R results in PKC phos-
phorylation of RKIP at Ser153 in sensory neurons.
We next sought to determine whether BK-induced PKC stim-
ulation also directs RKIP dimerization and association with
GRK2, using coIP analyses (Figure 5C). BK (200 nM; 5 min)
induced GRK2 co-immunoprecipitation with the RKIP dimer in
cytosolic lysates from serum-starved TG cultures, in a manner
sensitive to PKC inhibition (GFX, 10 mM; 5 min). These data
indicate that BK-induced PKC activation stimulates RKIP self-
dimerization and association with GRK2 in sensory neurons,
supporting PKC-dependent RKIP sequestration of GRK2.
RKIP Sequestration of GRK2 Modulates BK Priming
of DOR
In immortalized cells, RKIP facilitates DOR signaling (Kroslak
et al., 2001). Given that BK activation of PKC induces functional
DOR competence (Figure S3) (Patwardhan et al., 2005), GRK2
dissociation from PM DOR (Figure 2A), and RKIP phosphoryla-
tion and self-dimerization resulting in association with GRK2
(Figures 5B and 5C), we hypothesized that RKIP sequestration
of GRK2 governs BK priming of DOR in sensory neurons.
Figure 4. GRK2 Modulation of DOR-Mediated Antinociception
(A) Timeline for ODN injections and rat behavior protocol for BK priming of peripheral DOR antinociception.
(B) WCL from ipsilateral (ipsi-) and contralateral (contra-) DRG of rats treated with MM-ODN or GRK2 AS-ODN. *p < 0.05; ns, no significance; n = 3 independent
trials; one-way ANOVA Bonferroni post hoc; mean ± SEM.
(C–F) Time course for DPDPE inhibition of PGE2-induced allodynia in ipsilateral (C), mechanical; (D), thermal and contralateral (E), mechanical; (F), thermal
hindpaws. Paw withdrawal readings were measured 5 min and 10 min post-intraplantar (i.pl.) injection (vehicle or BK [25 mg], and 5-min intervals for 20 min
following second i.pl. injection (co-injection DPDPE [20 mg]/PGE2 [0.3 mg]); BK-induced allodynia: mechanical and thermal, ***p < 0.005 versus vehicle-treated
groups; DPDPE inhibition of PGE2-induced allodynia: mechanical, 20 min, *p < 0.05 (MM-ODN/BK), 25 min, **p < 0.01 (AS-ODN/BK), ***p < 0.005 (AS-ODN/Veh,
MM-ODN/BK); 30 min, *p < 0.05 (AS-ODN/Veh), **p < 0.01 (AS-ODN/BK, MM-ODN/BK); 35 min, ***p < 0.005 (MM-ODN/BK, AS-ODN/Veh, AS-ODN/BK) versus
(legend continued on next page)
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Figure 5. BK Modulation of RKIP Signaling
in Sensory Neurons
(A) Immunohistochemical expression of RKIP (red)
in rat TG and DRG with Topro (blue) to identify
nuclei. Scale bars, 50 mm (yellow) and 15 mm
(white). Confocal images are representative of four
independent trials.
(B) Cytosolic lysates from TG cultures serum-
starved for 18 hr and treated with vehicle (5 min)/
vehicle (5 min), BK (200 nM, 5 min)/vehicle, BK/
HOE-140 (10 mM, 5 min), or BK/GFX (GF 109203X,
10 mM, 5min). **p < 0.01 versus vehicle/vehicle, ns,
no significance; n = 3 independent trials; one-way
ANOVA Bonferroni post hoc; mean ± SEM.
(C) Cytosolic coIP from TG cultures serum-starved
for 18 hr and treated with vehicle (5 min)/vehicle
(5 min), vehicle/BK (200 nM, 5 min), or BK/GFX (GF
109203X, 10 mM, 5 min). *p < 0.05; ns = no signif-
icance; n = 3 independent trials; one-way ANOVA
Bonferroni post hoc; mean ± SEM.
See also Figure S4.We employed siRNA-mediated knock down of RKIP expres-
sion in sensory neuron cultures to evaluate the role of RKIP
in BK priming of DOR. To demonstrate the specificity of this
molecular approach in TG cultures, we assessed the efficiency
of RKIP knock down relative to b-actin and found a 65% reduc-
tion in normalized RKIP protein expression 1 day post-transfec-
tion (Figure 6A).
Next, we sought to determine whether BK priming of DOR
functional competence remained intact in DRG following
siRNA-mediated knock down of RKIP protein expression. BK
pretreatment (200 nM; 5 min) significantly increased DPDPE in-
hibition of KCl-evokedCa2+ influx inmock-transfected DRG (Fig-
ures 6B and 6C). However, in DRG transfected with FITC-RKIP
siRNA, there was no longer a BK-induced increase in DPDPE
inhibition of KCl-evoked Ca2+ influx. Furthermore, when we re-
introduced RKIP into FITC-RKIP siRNA-treated DRG (RKIP
Rescue), the effect on DPDPE-inhibition of KCl-evoked Ca2+
influx was restored. These data indicate that RKIP expression
is required for BK priming of DOR functional competence.
To determine whether PKC phosphorylation of RKIP is neces-
sary for BK priming of functional DOR competence in cultured
DRG, we overexpressed RKIP or a phospho-deficient mutant
(RKIP-S153A) and measured DOR activity in vehicle- and BK-
treated conditions. BK pretreatment (200 nM; 5 min) significantlyMM-ODN/Veh; thermal, **p < 0.01 MM-ODN/BK versus AS-ODN/Veh; 25–35, ***p < 0.005 versus groups b
two-way ANOVA Bonferroni post hoc; mean ± SEM.
(G and H) Quantified antinociceptive effect of DPDPE at 35min for mechanical (G) and thermal (H) readings. **
two-way ANOVA Bonferroni post hoc; mean ± SEM.
2692 Cell Reports 16, 2686–2698, September 6, 2016increased DPDPE inhibition of KCl-
evoked Ca2+ influx in GFP-positive DRG
neurons nucleofected with empty vector
(E.V.) or RKIP (Figure S4). However, in
GFP-positive DRG cultures nucleofected
with RKIP-S153A, BK was unable to
induce DPDPE inhibition of KCl-evokedCa2+ influx. These data demonstrate that PKC phosphorylation
of RKIP is required for BK-induced functional DOR competence
in sensory neurons.
GRK2 Modulation of DOR G Protein Coupling
The primary signaling event in GPCR activation involves G pro-
tein interaction (Rodbell et al., 1971). Following agonist stimula-
tion, DOR interacts with a heterotrimer G protein complex
comprised of an ai subunit and bg dimer (Alves et al., 2004).
Upon dissociation from the receptor, Gai and Gbg signal as
downstream effectors. Gb subunits function to inhibit VGCCs
(Herlitze et al., 1996; Ford et al., 1998). Given that BK enhances
the potency of DPDPE-mediated inhibition of VGCCs in sensory
neurons (Figures 1A and 1B), we investigated the possibility that
BKmight influence interactions betweenGb and DOR using coIP
analyses. In PM preparations from serum-starved, vehicle-
treated TG cultures, Gb co-immunoprecipitates with DOR (Fig-
ure 7A). Notably, there is an increase in Gb co-immunoprecipita-
tion with DOR following treatment with BK (200 nM; 5 min).
Conversely, there is a decrease in DOR-bound Gb in TG cultures
treated with DPDPE (1 mM; 15 min) following initial BK pretreat-
ment (Figure 7B). These data indicate that prior to ligand binding,
BK facilitates the coupling of Gb to DOR. Taken together with
our Ca2+ imaging data, these findings also indicate that Gb iselow baseline (BL) readings; n = 6 rats per group;
*p < 0.005; ns, no significance; n = 6 rats per group;
Figure 6. RKIP Modulation of Functional DOR Competence
(A) WCL from 2 hr serum-starved TG cultures transfected in mock fashion or with mismatch, RKIP, or FITC-RKIP siRNA. *p < 0.05, **p < 0.01, ns, no significance
versus mock; n = 3 independent trials; one-way ANOVA Bonferroni post hoc; mean ± SEM.
(B and C) Cumulative traces (B) and quantification (C) of DPDPE (1 mM) inhibition of KCl (50 mM)-evoked Ca2+ influx in DRG (mock-treated, transfected with FITC-
RKIP siRNA or FITC-RKIP siRNA followed by nucleofection RKIP and GFP cDNAs [RKIP Rescue]) pretreated with vehicle or BK (200 nM, 5 min) following 2 hr
serum-starvation. **p < 0.01; ns, no significance; n = 20–26 DRG/group; two-way ANOVA Bonferroni post hoc; mean ± SEM.cooperatively released to potentially act on second order targets
when DPDPE activates primed DOR.
Next, we hypothesized that the constitutive interaction be-
tween GRK2 and DOR may block the coupling of DOR to Gb.
For this, we utilized siRNA and coIP techniques in TG cultures
to validate the role of GRK2 in DOR coupling to Gb. BK pretreat-
ment (200 nM; 5 min) increased DOR-bound Gb in serum-
starved mock- and GRK2 siRNA-treated TG culture PM lysates
(Figure 7C). These data indicate that the absence of GRK2 alone
is not sufficient to recruit Gb to the receptor. To investigate
whether GRK2 overexpression impairs DOR coupling to Gb,
PM coIPs were conducted from TG cultures nucleofected with
GRK2 or E.V., serum-starved, and treated with vehicle or BK
(200 nM; 5 min). As expected, Gb co-immunoprecipitated with
DOR in vehicle-treated TG cultures nucleofected with E.V., while
BK treatment increased Gb co-immunoprecipitation with DOR.
GRK2 overexpression blocked the BK-dependent increase in
Gb association with DOR (Figure 7D). Thus, the constitutive as-
sociation between GRK2 and DOR attenuates Gb:receptor
coupling in sensory neurons. Together with our DOR-GRK2 as-
sociation and functional imaging studies, these findings suggest
that GRK2 hinders receptor coupling to Gb, such that Gb may
not inhibit VGCCs unless primed first by BK.
DISCUSSION
The phenomenon of peripheral DOR incompetence in the
periphery has been observed in vitro (Patwardhan et al., 2005,
2006) and in vivo (Stein et al., 1989; Rowan et al., 2009), and pre-treatment with an inflammatory stimulus is required for DOR acti-
vation, thereby promoting analgesia. However, a major gap in
knowledge existed concerning (1) why peripheral DOR remains
functionally incompetent under naive conditions, and (2) amech-
anism for DOR priming beyond PKC-dependence. This study
identifies two important conclusions that fill this gap. First, our
data illustrate that DOR responsiveness to agonist stimulation
in naive afferent terminals is impaired by a constitutive interac-
tion with GRK2 at the PM that prevents receptor coupling to
Gb, which subsequently prohibits VGCC inhibition. Second,
when peripheral sensory neurons undergo BK activation of
B2R, PKC directly phosphorylates RKIP. This initiates RKIP
self-dimerization and sequestration of GRK2. Consequently,
DOR can couple to Gb to inhibit VGCCs, which results in antino-
ciception. Within this framework we have identified pharmaceu-
tical targets that may enhance DOR-mediated analgesia.
Numerous reports in immortalized cell lines indicate that GRK2
phosphorylation of DOR occurs following stimulation by highly
efficacious agonists such as DPDPE (Guo et al., 2000; Kouhen
et al., 2000; Marie et al., 2008; Bradbury et al., 2009), deltorphin
II (Bradbury et al., 2009), and (+)BW373U86, as well as SNC 80
in hippocampal lysates (Pradhan et al., 2009). In response to
agonist stimulation, GRK2 hierarchically phosphorylates DOR
for phosphorylation site-specific receptor regulation (Kouhen
et al. 2000). The initial site phosphorylation, Ser363, promotes
uncoupling of activated DOR from G proteins and desensitizes
PMDOR,whereas the second phosphorylation site, Thr358, reg-
ulates receptor internalization. Although BK elicits an increase in
DOR competence (Figures 1A, 1B, 4C, 4D, 4G, and 4H), it doesCell Reports 16, 2686–2698, September 6, 2016 2693
Figure 7. GRK2 Hinders Peripheral DOR G Protein Coupling
(A and B) Crude PM coIP from TG cultures serum-starved for 18 hr and treated with vehicle or BK (200 nM, 5 min) (A) or vehicle or BK (200 nM, 5 min) then DPDPE
(1 mM, 15 min) (B). (A) *p < 0.05; ns, no significance; n = 3 independent trials; unpaired two-tailed Student’s t test; mean ± SEM.
(C) Crude PM coIP from TG cultures serum-starved for 2 hr following mock- or GRK2-siRNA nucleofection and treated with vehicle or BK (200 nM, 5 min).
*p < 0.05; n = 3 independent trials; two-way ANOVA Bonferroni post hoc; mean ± SEM.
(D) Crude PM coIP from TG cultures co-treated for 18 hr with empty vector (E.V.) or GRK2 cDNA nucleofection (overexpression) in serum-starvedmedia followed
by treatment with vehicle or BK (200 nM, 5 min). *p < 0.05; ns, no significance; n = 3 independent trials; unpaired two-tailed Student’s t test; mean ± SEM.not affect GRK2 phosphorylation of DOR at Ser363 (Figure 3A).
With no commercially available phospho-specific antibody for
DOR Thr358, we could not evaluate GRK2 phosphorylation of
the internalization residue. b-arrestin-2 mediates internalization
of DOR following GRK2 phosphorylation at Ser363 (Bradbury
et al., 2009). We report here that DPDPE and SNC 80, a b-ar-
restin-2-biased agonist in primary sensory neurons (Rowan
et al., 2014), equally inhibited KCl-evoked Ca2+ influx following
pretreatment by BK (Figure 1D), which suggests that b-ar-
restin-2 neither mediates constitutive DOR incompetence nor
BK-induced functional DOR competence. Furthermore, genetic
ablation of b-arrestin-2 has been reported to have no effect on
DOR-mediated inhibition of VGCCs or analgesia in the absence
or presence of inflammation (Pradhan et al., 2013). These data
suggest that the hierarchical nature of DOR phosphorylation by
GRK2 does not necessarily regulate DOR activity in sensory
neurons.
GRK2 regulation of GPCR coupling independent of receptor
phosphorylation has been reported for Gaq/11-coupled (Dicker
et al., 1999), Gas-coupled (Reiter et al. 2001), and Gai/o-coupled
receptors (Lembo et al., 1999; Namkung et al., 2009). In our over-
expression studies, we found that GRK2 suppression of DOR
signaling in DRG is not attributable to GRK2 kinase activity
because the ability of a kinase-deficient mutant to attenuate
DOR activity is indistinguishable from that of GRK2 (Figures 3B
and 3C). Furthermore, GRK2 overexpression also attenuates2694 Cell Reports 16, 2686–2698, September 6, 2016optimal DOR-G protein coupling (Figure 7D). These data impli-
cate that GRK2 protein-protein interaction with DOR, rather
than kinase activity and receptor phosphorylation, governs
DOR responsiveness to agonist stimulation in peripheral sensory
neurons. In immortalized cells, GRK2 constitutive association
with D2R attenuates receptor signaling and G protein coupling
independent of receptor phosphorylation by GRK2 (Namkung
et al., 2009). Whether GRK2 chronically downregulates GPCRs
other than DOR at the PM in sensory neurons remains to be
elucidated.
An orchestration of signaling events are likely necessary to
induce peripheral functional DOR competence in physiologically
relevant systems. BK receptors are fundamental to peripheral
opioid analgesia following inflammatory insult or after chronic
constriction injury (Cayla et al., 2012). In approximately half of
small-sized TG and DRG that overexpress DOR-GFP, a mild in-
crease in DOR trafficking to the PM is induced by BK (200 nM)
within 5–10 min (Pettinger et al., 2013). We did not observe any
notable differences in native DOR trafficking to the PM following
BK exposure (Figures 2A and 7A–7D); however, this effect could
be diluted in our cultures for biochemistry that included neurons
with sizes ranging from small to large along with support cells
(glial, etc.). In addition to an increase in DOR targeting to the
PM in small neurons, Pettinger et al. (2013) also observed a
doubling of CAP-sensitive TG neurons that respond to a DOR
agonist following BK (200 nM; 15 min) treatment. We also
observed this phenomenon in DRG; the total population of neu-
rons that responded to DPDPE rose from 22.9%–25.0% to
48.3%–52.9% following BK (200 nM; 5 min) treatment (Fig-
ure S2). Interestingly, our population data also revealed that
BK increased the total population of DRG that responded to
CAP (1 mM) from 50%–59.5% to 70.3%–79.4%. These data
are consistent with another report that found that approximately
70%of DRG are sensitive to this dose of CAP (Wang et al., 2008).
It has been demonstrated that BK lowers the threshold for heat-
activation of TRPV1 in DRG (Sugiura et al. 2002), and our data
suggest that BK also enhances CAP-sensitivity in DRG.
Comprehensively, results presented herein contribute to a
collection of findings that characterize mechanisms driving DOR
responsivity in multiple cellular models. For instance, allosteric
modulation of DOR by sodium ions (Fenalti et al., 2014) could
also allosterically affect constitutiveGRK2associationwith the re-
ceptor. Additionally, GRK2 association with DOR, which contrib-
utes to receptor internalization, most likely facilitates reduced
DOR responsiveness following biased ligand administration
(Pradhan et al., 2009). However, it is difficult to determinewhether
STAT5 signalosome formation with DOR is affected by chronic
GRK2 association with the receptor, since both utilize the same
C-terminal amino acids (Georganta et al., 2010). Importantly,
many of these studies utilize non-physiologicmodel cell systems,
including transfected immortalized cells, which can overexpress
receptor proteins relative to other endogenous regulatory
proteins. Results presented here employ more physiologically
relevant sensory neurons, providing analysis of endogenously ex-
pressed receptors and regulatory proteins that correlate more
with behavioral measures, and hence, clinical relevance.
B2R couples to multiple classes of G proteins, including Gaq
and Gas, and stimulates differential signaling cascades (Lieb-
mann and Bo¨hmer, 2000). B2R activation of Gaq primarily acti-
vates the PLC-PKC pathway, whereas Gas initiates cAMP-PKA
signaling. Additionally, studies in immortalized cell lines have
demonstrated that GRK2 can be directly phosphorylated by
either PKC (Chuang et al., 1995; Pronin and Benovic, 1997) or
PKA (Cong et al., 2001) to affect GPCR desensitization. We
found that PLC and PKC, but not PKA, were involved in BK-
induced GRK2 dissociation from PM DOR and BK priming of
DOR in sensory neurons (Figure S3). Indeed, work in neuroblas-
toma cells demonstrated PKC and GRK2mediate DOR desensi-
tization (Marie et al., 2008). Although the concentration of BK
used in our study (200 nM) activates B2R’s primary PLC-PKC
pathway, it may not sufficiently activate cAMP in DRG (Wang
et al., 2008). Thus, at higher concentrations of BK, it may be
possible that PKA contributes to functional DOR competence.
Although PKA was not investigated, Patwardhan et al. (2006)
demonstrated that PKC inhibition blocks peripheral DOR
competence induced by a more potent dose of BK (10 mM) in
sensory neurons.
The importance of BK priming on functional DOR competence
observed in vitro, by this study and others (Patwardhan et al.,
2005, 2006; Sullivan et al., 2015), was recapitulated in vivo. A
peripherally restrictive dose of DPDPE was unable to elicit an
anti-allodynic response unless primed by BK in MM-ODN-
treated rats. This finding is similar to observations in rats in the
absence of i.t. ODN treatments prior to behavioral experimenta-tion (Rowan et al., 2009; Sullivan et al., 2015). This experiment
identified that downregulation of GRK2 eliminates the need
for BK priming of DOR-mediated anti-allodynia. Ferrari et al.
(2012) found that 3 days of i.t. GRK2 AS-ODN administration pro-
duces a 39%decrease in GRK2 protein expression in the saphe-
nous nerve, yet we observed near-ablation of GRK2 protein at
the level of the DRG. The difference in knock down suggests
that the support cells adjacent to distal portions of the afferent
nerve were unaffected by i.t. GRK2 AS-ODN administration.
Residual GRK2 that remains in fibroblasts, microglia, and other
cells that run adjacent from the saphenous nerve to the periph-
eral terminals in the hindpaw may account for the enhanced
onset of DPDPE anti-allodynia following BK priming in GRK2
knock down animals without comparable changes in magnitude
or duration of BK-induced mechanical and thermal allodynia.
Because BK priming of DPDPE inhibition of PGE2-induced allo-
dynia is mediated by PKC (Rowan et al., 2009), we theorize that
BK may have been needed to induce the PKC-dependent
sequestration of remaining GRK2 in order to behaviorally
observe the earlier thermal anti-allodynic effects of DPDPE.
Our behavioral data also suggest that GRK2 chronically
downregulates peripheral DOR anti-nociception. However, we
observed a transient, enhanced thermal allodynia 5min following
DPDPE/PGE2 co-injection in GRK2 AS-ODN-treated rats.
Similarly, PGE2-induced thermal allodynia was increased in
two mouse models with reduced GRK2 expression: sensory
neuron-specific heterozygous GRK2 mice and tamoxifen-
treated inducible whole body heterozygous GRK2 mice (Eijkel-
kamp et al., 2010). Another study in GRK2 AS-ODN-treated
rats found that reduced GRK2 expression enhances PGE2-
induced mechanical allodynia (Ferrari et al., 2012). However,
our results demonstrate that PGE2-induced mechanical allody-
nia is fully inhibited by DPDPE in GRK2 AS-ODN-treated rats
(Figures 4C and 4G). Together with our findings, these data sug-
gest that, although it can enhance the response to certain inflam-
matory mediators (including PGE2, not BK), targeting GRK2 can
also be beneficial by enhancing peripheral opioid analgesia.
In conclusion, experimental results demonstrate that GRK2
chronically downregulates DOR functional competence at the
PM in peripheral sensory neurons, as well as peripheral DOR
anti-nociception in vivo. Prior to this study, there was no identi-
fied mechanism for DOR priming by BK beyond PKC-depen-
dence. The phenomenon of peripheral DOR incompetence in
the absence of an inflammatory priming stimulus would be
expected to limit the effectiveness of locally administered DOR
agonists to individuals with severe inflammatory pain. Because
chronic GRK2 association with DOR contributes to receptor
incompetence in the absence of inflammation, we propose that
peripherally targeting GRK2 in combination with DOR may
improve analgesic efficacy in non-inflammatory pain conditions.EXPERIMENTAL PROCEDURES
All procedures utilizing animals were approved by the Institutional Animal Care
and Use Committee of University of Texas Health Science Center at San An-
tonio and were conducted in accordance with the policies for the ethical treat-
ment of animals established by the NIH. Every effort was made to limit animal
discomfort and the number of animals used.Cell Reports 16, 2686–2698, September 6, 2016 2695
Animals
Adult male Sprague-Dawley rats (Charles River Laboratories) weighing 200–
250 g (biochemistry, Ca2+ imaging) or 350–400 g (oligodeoxynucleotide-
treated) were used in this study. Animals were housed in clean cages with a
12 hr light/dark cycle for 1 week with food and water ad libitum before use.
Neuronal Cultures
For biochemistry, trigeminal ganglia (TG) were dissected bilaterally from male
rats. TG were dissociated by 30 min collagenase (Worthington) treatment fol-
lowed by 30 min trypsin (Sigma-Aldrich) treatment, with gentle rocking every
10 min. Cells were then resuspended in complete media (DMEM, Invitrogen)
supplemented with 10% fetal bovine serum (Invitrogen), 100 ng/ml nerve
growth factor (NGF; Harlan Laboratories), mitotic inhibitors (Sigma-Aldrich),
1% penicillin/streptomycin (Invitrogen), and 1% glutamine (Sigma-Aldrich)
and plated on poly-D-lysine-coated plates (Corning). Cultures were main-
tained at 37C and 5% CO2 and grown for 5–6 days with media changed the
following day and every 2 days thereafter. TG were utilized for biochemical ex-
periments to satisfy NIH requirements to reduce animal use in research.
For Ca2+ imaging, TG or dorsal root ganglia (DRG) dissected bilaterally at L4-
L6 were dissociated by 40 min co-treatment with collagenase (Worthington)
and dispase (Sigma-Aldrich) with gentle rocking every 10 min. Next, cells
were resuspended in complete media and plated on poly-D-lysine/laminin-
coated coverslips (BD Biosciences). Media was changed the following day
and experiments were conducted within 24–48 hr of initial culture.
Knock down and overexpression strategies are described in the Supple-
mental Experimental Procedures.
Crude Membrane Preparation
Primary TGcultureswerepretreated as indicated.Cellswere harvestedandho-
mogenized in homogenization buffer (25 mMHEPES, 25 mM sucrose, 1.5 mM
MgCl2, 50 mM NaCl [pH 7.4], 1 mM sodium pyrophosphate, 1 mM sodium
orthovanadate [Sigma-Aldrich], 1 mg/ml pepstatin [Sigma-Aldrich], 1 mg/ml
leupeptin [Sigma-Aldrich], 1 mg/ml aprotinin [Sigma-Aldrich], and 100 nm
phenylmethylsulphonyl fluoride [PMSF, Sigma-Aldrich]) with 20 strokes using
a Potter-Elvehjem pestle and glass homogenizer tube. Homogenates were
placed on ice for 15 min incubation and then centrifuged at 1,000 3 g for
1 min to remove nuclei and unlysed cells from the homogenate. Resulting su-
pernatantwas centrifugedat 16,0003g for 30min at 4C to separate cellmem-
brane proteins from cytosolic proteins. Cytosolic supernatant was separated
from the pellet (crude membrane fraction), which was re-suspended in 250 ml
homogenization buffer containing 1%TritonX-100 (Fisher Scientific). Total pro-
tein was quantified using Bradford assay (Sigma-Aldrich) prior to co-immuno-
precipitation (coIP). For coIP protocol and western blot (WB) analysis details,
please see the Supplemental Experimental Procedures.
Ca2+ Imaging
Fura-2 AM was used to image individual neurons within a population of
cultured ganglionic cells. Following 2 hr serum-starvation, cells were loaded
with fura-2 AM (1 mM; Molecular Probes) in the presence of pluronic F-127
(0.04%;Molecular Probes) for 1 hr at 37C in the dark, in standard extracellular
solution (SES) containing (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10
HEPES, 10 D-(+)-glucose, pH 7.40. Cells were viewed on an inverted Nikon
Eclipse Ti-Umicroscope fittedwith a 403/1.35 numerical aperture Fluor objec-
tive and imaged usingMetaFluor System for Ratio Fluorescence (MetaMorph).
Fluorescent images were taken alternately every 3 s with 340 and 380 nm exci-
tation wavelengths in combination with a 510 nm emission filter with 200-ms
exposure. Ratio of DF340/F380 was plotted for each cell versus time. Intracel-
lular Ca2+ levels were analyzed as DF340/F380 ratios background corrected
and normalized to initial value, R0. Corresponding filters were used to select
FITC-siRNA- or GFP-positive DRG.
To quantify DOR activity in sensory neurons, Ca2+ imaging was used to
assess DOR agonist inhibition of KCl-evoked Ca2+ influx (Figure S1). Although
time in culture varied by protocol, BK pretreatment significantly enhanced
DPDPE inhibition of KCl-evoked Ca2+ influx at all time points utilized in this
study (Figure S2). For details on primary afferent neuron selection, opioid inhi-
bition of KCl-evoked Ca2+ influx protocol, equations, and drug stock concen-
trations, refer to the Supplemental Experimental Procedures.2696 Cell Reports 16, 2686–2698, September 6, 2016Electrophysiology
Whole-cell patch-clamp recordings were used to measure DOR-mediated in-
hibition of VGCCs in cultured rat DRG neurons (20–35 pF). Following 2 hr incu-
bation in 2% serum at 37C, whole-cell patch-clamp configuration was per-
formed at room temperature on neurons viewed on an upright Nikon Eclipse
E600FN microscope fitted with a 403/0.80W numerical aperture objective.
Borosilicate glass patch clamp capillaries (Sutter) were polished to resistances
of 2–4 MU and filled with internal solution containing (in mM): 140 CsCl,
10 EGTA, 1 CaCl2, 1 MgCl2, 10 HEPES, 4 Mg-ATP, 0.3 Na-GTP, pH 7.20.
Whole-cell configuration was established in extracellular solution containing
(in mM): 140 TEA-Cl, 2 CaCl2, 1 MgCl2, 10 HEPES, 10 D-glucose, pH 7.30. Ax-
opatch 200B amplifier and pCLAMP9.6 software (Molecular Devices, Axon)
were used to acquire and analyze data. From a holding potential of 60 mV,
VGCC currents were activated by single pulse from 60 to 0 mV (50-ms dura-
tion). Waveform was applied repetitively every 10 s. DPDPE (1 s a was applied
via local application. Coverslips were incubated at room temperature for
10 min either with vehicle or with BK (200 nM). All recorded cells sized 20–
35 pF were included in analysis.
Behavioral Test for BK Priming of DOR Functional Competence
This study utilized custom GRK2 antisense (AS) and mismatch (MM) oligo-
deoxynucleotide (ODN) sequences synthesized by Invitrogen first described
by Ferrari et al. (2012). ODNs were intrathecally (i.t.) administered to rats anes-
thetized with 2.5% isoflurane once daily for 3 days prior to behavioral testing.
On day 4, BK-induced DPDPE inhibition of prostaglandin (PGE2)-induced ther-
mal and mechanical allodynia was assessed in ODN-treated rats to determine
the role of GRK2 in BK priming of peripheral DOR antinociception. All measure-
ments were conducted by blinded observers. For further explanation, see the
Supplemental Experimental Procedures.
Statistics
GraphPad Prism 5.0 was used for statistical analyses (GraphPad Software).
Quantitative data were expressed as mean ± SEM. Statistical significance
was determined by Student’s unpaired t test, one-way ANOVA, or two-way
ANOVAwith Bonferroni post hoc analyses as needed. p < 0.05was considered
statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.07.084.
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